Balance Sheet
Cash Flow Statement
Beginning Cash BalanceBeginning Cash BalanceCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Shares IssuedShares OutstandingShares Outstanding
Ratios

Drugs Made In America Acquisition (DMAA) Shares Issued (2025)

Drugs Made In America Acquisition filings provide 1 years of Shares Issued readings, the most recent being -$225.6 million for Q4 2025.

  • Quarterly Shares Issued changed N/A to -$225.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.2 million through Dec 2025, changed N/A year-over-year, with the annual reading at $3.2 million for FY2025, 9042.86% up from the prior year.
  • Shares Issued hit -$225.6 million in Q4 2025 for Drugs Made In America Acquisition, down from $225.6 million in the prior quarter.
  • Across five years, Shares Issued topped out at $228.8 million in Q1 2025 and bottomed at -$225.6 million in Q2 2025.